---
title: "STTT：港中大团队发现肠癌耐药新机制！YTHDF1可诱导肠癌细胞获得干性"
date: 2026-01-17T15:23:34Z
draft: ["false"]
tags: [
  "fetched",
  "奇点肿瘤探秘"
]
categories: ["Acdemic"]
---
STTT：港中大团队发现肠癌耐药新机制！YTHDF1可诱导肠癌细胞获得干性 by 奇点肿瘤探秘
------
<div><section><section><section><section data-pm-slice="0 0 []"><span data-pm-slice="0 0 []"><span leaf="">*仅供医学专业人士阅读参考</span></span></section><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/KOKAbfNqiaJLcffhq0DueBvaH7TdYyV9sXlK2Av1azHlgshCVL0u4fS9wiad4yMsWlAApKJ6uhNIF2GNAWNqEnxg/640?wx_fmt=png&amp;from=appmsg&amp;randomid=v45c540m&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp#imgIndex=0" alt="图片" data-ratio="0.3333333333333333" data-s="300,640" data-type="png" data-w="1080" data-croporisrc="https://mmbiz.qpic.cn/sz_mmbiz_png/KOKAbfNqiaJLcffhq0DueBvaH7TdYyV9sXlK2Av1azHlgshCVL0u4fS9wiad4yMsWlAApKJ6uhNIF2GNAWNqEnxg/0?wx_fmt=png&amp;from=appmsg" data-cropselx2="538" data-cropsely2="179" data-backw="538" data-backh="179" data-imgfileid="100018536" data-aistatus="1" src="https://mmbiz.qpic.cn/sz_mmbiz_png/KOKAbfNqiaJLcffhq0DueBvaH7TdYyV9sXlK2Av1azHlgshCVL0u4fS9wiad4yMsWlAApKJ6uhNIF2GNAWNqEnxg/640?wx_fmt=png&amp;from=appmsg&amp;randomid=v45c540m&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp#imgIndex=0"></section><p><span><span leaf=""><br></span></span></p><p><span><span leaf=""><span textstyle="">结直肠癌（CRC）是全球范围内发病率第三、死亡率第二的常见恶性肿瘤。尽管手术和辅助化疗已成为临床标准治疗手段，但近四成的II-III期患者仍面临复发风险，且转移性CRC患者的治疗效果普遍不佳。</span></span></span></p><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">为何癌细胞总能“卷土重来”？近年来的研究逐渐将焦点投向一群特殊的细胞——</span><span textstyle="">肿瘤干细胞</span><span textstyle="">。它们如同潜伏在肿瘤中的种子，不仅具有无限自我更新的能力，更对常规化疗药物表现出惊人的抵抗力。即便大部分肿瘤细胞被药物清除，这群顽强的细胞仍能存活下来，成为复发和转移的根源。因此，揭示肿瘤干细胞存活与耐药的深层机制，是突破当前治疗瓶颈、改善患者预后的关键。</span></span></p><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">近日，</span></span><span leaf=""><span textstyle="">Signal Transduction and Targeted Therapy volume</span><span textstyle="">杂志发表了</span></span><span leaf=""><span textstyle="">香港中文大学于君、黄子隽团队的最新论文。他们</span></span><span leaf=""><span textstyle="">利用多组学分析与小鼠模型发现，蛋白质YTHDF1能够通过对RNA修饰激活CRC细胞的NOTCH1信号通路，从而驱动其干细胞特性，促进肿瘤发生以及化疗耐药。他们还结合患者临床数据进行分析，揭示YTHDF1表达与干细胞标志物CD133、LGR5显著正相关，且高表达患者化疗反应差</span><span textstyle="">。</span></span></p><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">针对这一发现，研究团队</span><span textstyle="">开发了两种靶向YTHDF1的治疗策略，在小鼠模型中可协同增强常用化疗药物奥沙利铂、5-氟尿嘧啶的疗效，为克服结直肠癌化疗耐药提供了新的治疗靶点和策略</span><span textstyle="">。</span></span></p><p><span leaf=""><br></span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/KOKAbfNqiaJIcmPtoZdG92pkvKAH2ofqbPa7lWJUUE5pHYvGzvP5JVPkc5vmsnIgpk9oT41Fot4tJzg4TrHOJmg/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.41217150760719223" data-s="300,640" data-type="png" data-w="723" type="block" data-imgfileid="100020175" data-aistatus="1" src="https://mmbiz.qpic.cn/sz_mmbiz_png/KOKAbfNqiaJIcmPtoZdG92pkvKAH2ofqbPa7lWJUUE5pHYvGzvP5JVPkc5vmsnIgpk9oT41Fot4tJzg4TrHOJmg/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">RNA的N</span></span><sup><span leaf=""><span textstyle="">6</span></span></sup><span leaf=""><span textstyle="">-甲基腺苷（m</span></span><sup><span leaf=""><span textstyle="">6</span></span></sup><span leaf=""><span textstyle="">A）修饰是肿瘤进展中的重要表观遗传调控方式。作为</span><span textstyle="">m</span></span><sup><span leaf=""><span textstyle="">6</span></span></sup><span leaf=""><span textstyle="">A阅读器蛋白，YTHDF1</span><span textstyle="">的身份十分可疑，被发现在结直肠癌（CRC）中高表达，并被报道与肿瘤生长和免疫调节相关。</span></span></p><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">为探究YTHDF1是否会通过影响CRC干性来做手脚，研究团队首先在CRC干细胞系和患者来源类器官模型中进行了体外功能验证。</span></span></p><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">他们发现，</span><span textstyle="">过表达YTHDF1能显著增强CRC干细胞的自我更新能力、成球形成和细胞活力，而敲低YTHDF1则产生相反效果</span><span textstyle="">。关键在于，当研究人员将YTHDF1蛋白中负责识别m</span></span><sup><span leaf=""><span textstyle="">6</span></span></sup><span leaf=""><span textstyle="">A修饰的关键氨基酸突变后，其促干性的能力完全消失，这证明YTHDF1的功能严格依赖于其阅读器特性。</span></span></p><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">不仅如此，小鼠实验结果表明</span></span><span leaf="" data-pm-slice='1 1 ["para",{"tagName":"section","attributes":{"style":"box-sizing: border-box; font-style: normal; font-weight: 400; text-align: justify; font-size: 16px; color: rgb(62, 62, 62);"},"namespaceURI":"http://www.w3.org/1999/xhtml"},"para",{"tagName":"section","attributes":{"style":" margin: 0px 0% 20px;  box-sizing: border-box; "},"namespaceURI":"http://www.w3.org/1999/xhtml"},"para",{"tagName":"section","attributes":{"style":"font-size: 15px; line-height: 1.9; padding: 0px 20px; letter-spacing: 0px; box-sizing: border-box;"},"namespaceURI":"http://www.w3.org/1999/xhtml"},"para",{"tagName":"p","attributes":{"style":"margin: 0px; padding: 0px; box-sizing: border-box;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span textstyle="">YTHDF1具有促肿瘤作用。</span></span><span leaf=""><span textstyle="">为更真实地模拟肿瘤在体内的发生过程，研究者构建了肠干细胞（Lgr5</span></span><sup><span leaf=""><span textstyle="">+</span></span></sup><span leaf=""><span textstyle="">）特异性</span></span><em><span leaf=""><span textstyle="">Ythdf1</span></span></em><span leaf=""><span textstyle="">基因修饰小鼠。结果发现，</span><span textstyle="">当Lgr5</span></span><sup><span leaf=""><span textstyle="">+</span></span></sup><span leaf=""><span textstyle="">细胞过表达</span></span><em><span leaf=""><span textstyle="">Ythdf1</span></span></em><span leaf=""><span textstyle="">时，无论是自发肿瘤模型还是化学诱导模型，小鼠的CRC肿瘤发生都显著加速，肿瘤数量增多、负荷加重，且细胞增殖活跃、凋亡受抑</span><span textstyle="">；反之，在Lgr5</span></span><sup><span leaf=""><span textstyle="">+</span></span></sup><span leaf=""><span textstyle="">细胞中敲除</span></span><em><span leaf=""><span textstyle="">Ythdf1</span></span></em><span leaf=""><span textstyle="">则能抑制肿瘤发生。</span></span></p><p><span leaf=""><br></span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/KOKAbfNqiaJIcmPtoZdG92pkvKAH2ofqbGdeHZmHAbaF6eiaPu2cpvoWmBibOibUuEuB3D6h9X3CRpHHZiaN49yMazA/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.5990740740740741" data-s="300,640" data-type="png" data-w="1080" type="block" data-imgfileid="100020176" data-aistatus="1" src="https://mmbiz.qpic.cn/sz_mmbiz_png/KOKAbfNqiaJIcmPtoZdG92pkvKAH2ofqbGdeHZmHAbaF6eiaPu2cpvoWmBibOibUuEuB3D6h9X3CRpHHZiaN49yMazA/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">这一系列证据表明，YTHDF1确实能够赋予CRC干细胞特性以及更强的肿瘤进展能力。</span></span></p><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">机制探索上，通过整合多组学测序分析，研究团队发现NOTCH1信号通路是YTHDF1的关键下游靶点。</span><span textstyle="">YTHDF1直接结合到NOTCH1 mRNA的m</span></span><sup><span leaf=""><span textstyle="">6</span></span></sup><span leaf=""><span textstyle="">A修饰位点上，像加速器一样促进其翻译过程，从而激活完整的NOTCH信号通路</span><span textstyle="">，而已知NOTCH通路是维持癌症干细胞特性的核心调控环节。</span></span></p><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">在患者组织样本中，YTHDF1与NOTCH1蛋白水平呈现显著正相关</span><span textstyle="">。小鼠实验则显示，无论是敲低NOTCH1还是使用NOTCH抑制剂DAPT，都能有效逆转YTHDF1过表达所引起的干性增强和肿瘤生长，确立了m</span></span><sup><span leaf=""><span textstyle="">6</span></span></sup><span leaf=""><span textstyle="">A-YTHDF1-NOTCH1调控通路。</span></span></p><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">除了通过驱动肿瘤干性来推动CRC发展，YTHDF1还能促进CRC化疗耐药。研究者们发现，</span><span textstyle="">过表达YTHDF1的CRC干细胞系和类器官，对临床一线药物奥沙利铂和5-氟尿嘧啶都表现出显著耐药性，药物处理后细胞凋亡减少，DNA损伤标志物p-H2AX水平降低</span><span textstyle="">。</span></span></p><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">体内实验结果同样如此，小鼠过表达</span></span><em><span leaf=""><span textstyle="">Ythdf1</span></span></em><span leaf=""><span textstyle="">时，这两种化疗药物的疗效大打折扣；相反，敲低</span><span textstyle="">Ythdf1</span><span textstyle="">则能唤醒CRC干细胞对化疗的敏感性，增强药物诱导的DNA损伤和细胞凋亡。</span></span></p><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">基于上述机制，研究团队探索了两种靶向YTHDF1的治疗策略。</span><span textstyle="">一是采用纳米颗粒递送YTHDF1 siRNA（VNP-siYTHDF1），二是使用天然小分子抑制剂丹酚酸C。</span><span textstyle="">两种方法均能有效抑制肿瘤生长，且与化疗药物联用时表现出显著的协同增效作用，肿瘤增殖被进一步抑制，凋亡显著增加。重要的是，这些靶向治疗在小鼠模型中表现出良好的安全性，为临床转化提供了重要依据。</span></span></p><p><span leaf=""><br></span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/KOKAbfNqiaJIcmPtoZdG92pkvKAH2ofqbfHePIJuyMrZiaKZhDZ3EtvDMgkHAFQgmXQDuL99lA2PV2qOGXU4wHRQ/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.5935185185185186" data-s="300,640" data-type="png" data-w="1080" type="block" data-imgfileid="100020177" data-aistatus="1" src="https://mmbiz.qpic.cn/sz_mmbiz_png/KOKAbfNqiaJIcmPtoZdG92pkvKAH2ofqbfHePIJuyMrZiaKZhDZ3EtvDMgkHAFQgmXQDuL99lA2PV2qOGXU4wHRQ/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">最后，通过对多个独立患者队列的生物信息学分析，研究者发现</span><span textstyle="">YTHDF1的表达与CD133、LGR5等干细胞标志物显著正相关，且高表达YTHDF1的患者往往对化疗反应较差</span><span textstyle="">。这从临床角度进一步印证了YTHDF1在调节肿瘤干性和化疗耐药中的关键作用。</span></span></p><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">总之，本研究阐明了YTHDF1通过m</span></span><sup><span leaf=""><span textstyle="">6</span></span></sup><span leaf=""><span textstyle="">A依赖的方式促进NOTCH1翻译，进而增强CRC干细胞特性与化疗耐药的信号通路。</span></span></p><p><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">从转化医学角度看，靶向YTHDF不仅可特异性抑制CRC干细胞的自我更新，还能避免传统NOTCH抑制剂引起的广泛毒性，具有更好的临床适用性。此外，YTHDF1表达水平可能作为预测CRC化疗反应的生物标志物，助力个体化治疗决策。</span></span><span><span leaf=""><br></span></span></p><p><span><span leaf=""><br></span></span></p><p><span><span leaf=""><span textstyle="">未来研究或进一步探索YTHDF1与其他m</span></span></span><sup><span leaf=""><span textstyle="">6</span></span></sup><span><span leaf=""><span textstyle="">A调控因子（如METTL3、ALKBH5）在CRC干性中的协同作用，以及其在肿瘤微环境调控中的角色。</span></span></span></p><p><span><span leaf=""><br></span></span></p><span leaf=""><span textstyle="">欢迎大家关注我们在小宇宙上的博客栏目——药研片语，和我们一起关注未来药物研发的趋势~</span></span><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/KOKAbfNqiaJKXhlIOPmFRM45yJWetibickmDlWxzqPNsM0ibJ7fn2czE1DqChcgeQ91TxZfBZxxHPHQQuY0bicrTkHw/640?wx_fmt=jpeg&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp#imgIndex=3" alt="图片" data-ratio="1.511111111111111" data-s="300,640" data-type="jpeg" data-w="1080" type="block" data-croporisrc="https://mmbiz.qpic.cn/sz_mmbiz_jpg/KOKAbfNqiaJKXhlIOPmFRM45yJWetibickmlKeX3HYWONuRvpyRvNut4S6P9hoztHOsMRuwM7PUxzoxOkibq0ovyGA/0?wx_fmt=jpeg&amp;from=appmsg" data-cropx2="1236" data-cropy2="1867.7843866171004" data-imgfileid="100019960" data-aistatus="1" src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/KOKAbfNqiaJKXhlIOPmFRM45yJWetibickmDlWxzqPNsM0ibJ7fn2czE1DqChcgeQ91TxZfBZxxHPHQQuY0bicrTkHw/640?wx_fmt=jpeg&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp#imgIndex=3"></section><p><span><span leaf=""><span textstyle="">参考文献：</span></span></span></p><p><span><span leaf=""><span textstyle="">[1]Cheung, H., Chen, H., Chen, D. et al. YTHDF1 targets the chemotherapy response by suppressing NOTCH1-induced stemness in colorectal cancer. Sig Transduct Target Ther 10, 409 (2025). https://doi.org/10.1038/s41392-025-02507-1</span></span></span></p><section data-pm-slice="0 0 []" nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/KOKAbfNqiaJLuPGzb5p6meFcibT8xA5b4m8l5fhsiax8LjYgia6icxBJicVxmVEubYNasfVwXv5yu9zB5GNiaImqVicS6A/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;randomid=o3trcnr7&amp;tp=webp#imgIndex=5" alt="图片" data-ratio="0.5004995004995005" data-s="300,640" data-type="other" data-w="1001" data-backw="538" data-backh="269" data-imgfileid="100017998" data-aistatus="1" src="https://mmbiz.qpic.cn/sz_mmbiz_png/KOKAbfNqiaJLuPGzb5p6meFcibT8xA5b4m8l5fhsiax8LjYgia6icxBJicVxmVEubYNasfVwXv5yu9zB5GNiaImqVicS6A/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;randomid=o3trcnr7&amp;tp=webp#imgIndex=5"></section><p><span><span data-pm-slice="0 0 []"><span leaf="">本文作者丨张艾迪</span></span></span></p></section></section></section><p><mp-style-type data-value="10000"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/lMCBMmNTrDaUhR-vpmMuCw",target="_blank" rel="noopener noreferrer">原文链接</a>
